Last mentioned: Feb 27, 2026
EU Expansion
Positive CHMP opinion received, enabling commercialization in the European Union.
Public Offering
Crinetics raises capital, bringing total cash position to $1.4 billion.
NDA Submission
Planned submission of paltusotine New Drug Application to the FDA.
Phase 3 Initiation
Anticipated start of Phase 3 trials for atumelnant in CAH and Cushing's disease.
Q4 Milestone
Over 200 enrollment forms and 125 unique prescribers recorded for Palsonify.
Earnings Call
Management confirms commercial readiness and pipeline acceleration.
Palsonify Launch
Crinetics initiates U.S. commercial launch of Palsonify for acromegaly.
PATHFNDR-2 Success
Completion of Phase 3 trial for paltusotine in acromegaly with positive results.
Q4 2025 earnings reports highlight a strategic shift toward AI-integrated hardware and high-margin services, with Aeva securing a pivotal NVIDIA partnership and Arlo achieving record SaaS metrics. Meanwhile, Crinetics successfully launched Palsonify, backed by a massive $1.4 billion cash reserve to fuel global expansion.
The Q4 2025 earnings cycle highlights a significant shift toward recurring revenue and high-performance computing (HPC) across the hardware and biotech sectors. Arlo Technologies achieved a landmark Rule of 40 score, while TeraWulf and Aeva Technologies signaled deeper integrations into the AI infrastructure ecosystem.
The Q4 2025 earnings season highlights a divergence between high-growth DTC brands like FIGS and Arlo, which are successfully leveraging recurring services, and industrial tech firms like PureCycle and Aeva transitioning into full-scale production. While margin pressures from tariffs persist, robust cash positions and strategic partnerships with giants like NVIDIA are fortifying market leaders.
Crinetics Pharmaceuticals (CRNX) reported Q4 2025 results, highlighting critical progress in its endocrine pipeline and preparations for the commercial launch of paltusotine. Alongside results from MDxHealth and Baldwin, the earnings cluster reflects a strategic transition for mid-cap healthcare and service firms navigating the 2026 market landscape.
Crinetics Pharmaceuticals reported strong Q4 2025 results, highlighting the successful completion of Phase 3 trials for paltusotine and preparations for a 2026 New Drug Application (NDA). The company is positioning itself for a major commercial pivot in endocrine disorders, supported by a robust balance sheet and positive data for its second lead candidate, atumelnant.